多发性硬化

近两年的全球研究 36,717L2

2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。

• 2026-12
  [THE EVALUATION OF EFFICIENCY OF REORGANIZATION OF MEDICAL CARE UNDER DISSEMINATED SCLEROSIS ON THE BASIS OF ANALYSIS OF DYNAMICS OF TREATMENT WITH MEDICATIONS ALTERING COURSE OF DISSEMINATED SCLEROSIS]
  Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny · DOI · Europe PMC
• 2026-12
  Exploring causal correlations between oily fish intake and multiple sclerosis: A two-sample Mendelian randomization study
  Asia Pacific journal of clinical nutrition · DOI · Europe PMC
• 2026-09病例报告
  Possible Contribution of Multiple Sclerosis Pathology to Treatment-Resistant Schizophrenia: A Case Study
  Neuropsychopharmacology reports · DOI · Europe PMC
• 2026-08病例报告
  Pearls & Oy-sters: Bilateral Neuropathic Facial Pain With Autonomic Features and Neurovascular Contact
  Neurology · DOI · Europe PMC
• 2026-08
  Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
  Neurology · DOI · Europe PMC
• 2026-08
  A Faster Way to Diagnose Multiple Sclerosis: The Central Vein Sign in Routine Clinical Practice
  Neurology. Clinical practice · DOI · Europe PMC
• 2026-07
  Presynaptic release-regulating C5a receptors in the spinal cord of healthy mice and of animals suffering from experimental autoimmune encephalomyelitis: impact of the C5aR antagonist DF2593A
  Neuropharmacology · DOI · Europe PMC
• 2026-07
  The transcriptional cortical response to daily torpor in <i>Phodopus sungorus</i>
  Life science alliance · DOI · Europe PMC
• 2026-07
  Network dynamics under neuronal degradation: A comparison between modular and small-world topologies
  Computer methods and programs in biomedicine · DOI · Europe PMC
• 2026-07
  The burden of noncommunicable and injury-related nervous system disorders in the Americas, 1990-2023: an analysis of the Global Burden of Disease Study 2023
  Lancet regional health. Americas · DOI · Europe PMC
• 2026-07
  Dietary intake and nutritional status in multiple sclerosis and associations with disease phenotype and management: A case-control study
  Journal of clinical neuroscience : official journal of the Neurosurgic · DOI · Europe PMC
• 2026-07
  Factors influencing quality of life in multiple sclerosis patients in Northwest Ethiopia: a multicentre cross-sectional study
  Annals of medicine · DOI · Europe PMC
• 2026-07综述
  Dietary regimens and cognitive function in multiple sclerosis: a systematic review
  Brain, behavior, & immunity - health · DOI · Europe PMC
• 2026-07
  An immunoinformatics-derived multi-epitope DNA vaccine targeting the Micropterus salmoides rhabdovirus G protein elicits protective immunity in largemouth bass
  Fish & shellfish immunology · DOI · Europe PMC
• 2026-06综述
  Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry
  Bioactive materials · DOI · Europe PMC
• 2026-06
  Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson's
  Experimental neurology · DOI · Europe PMC
• 2026-06
  From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis
  Journal of medical economics · DOI · Europe PMC
• 2026-06综述
  HSP27 in autoimmune diseases: Context-dependent regulation and clinical potential
  Biochimica et biophysica acta. Molecular basis of disease · DOI · Europe PMC
• 2026-06
  Pseudotumoral multiple sclerosis: unveiling its clinical and imaging characteristics
  Journal of clinical neuroscience : official journal of the Neurosurgic · DOI · Europe PMC
• 2026-06
  Graded hypergravity is associated with large-scale reorganization of resting-state cortical networks: EEG evidence from a neurological inactivity phenotype
  IBRO neuroscience reports · DOI · Europe PMC

国家医保药品目录中点名本病的药品 8L2

出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。

• 奥法妥木单抗注射液乙类谈判药品
  限成人复发型多发性硬化(RMS)。
• 奥瑞利珠单抗注射液乙类谈判药品
  限：1.成人复发型多发性硬化；2.成人原发进展型多发性硬化。
• 富马酸二甲酯肠溶胶囊乙类西药
  限成人复发型多发性硬化(RMS)。
• 氨吡啶缓释片乙类西药
  限多发性硬化合并步行障碍(EDSS评分4-7分)的成年患者。
• 特立氟胺片乙类西药
  限常规治疗无效的多发性硬化患者。甲 ★(850) 甲氨蝶呤 口服常释剂型
• 盐酸奥扎莫德胶囊乙类谈判药品
  限成人复发型多发性硬化。
• 盐酸芬戈莫德胶囊乙类西药
  限10岁及以上患者复发型多发性硬化(RMS)的患者。
• 西尼莫德片乙类西药
  限成人复发型多发性硬化的患者。

境外已获批用于本病的药物 25L2

欧盟 19 项、美国 6 项。同一药物在两地各批一次的，会分别列出。

• Betaferon欧盟1995-11-30
  interferon beta-1b
  官方记录
• Avonex欧盟1997-03-13
  interferon beta-1a
  官方记录
• Tysabri欧盟2006-06-27
  natalizumab
  官方记录
• Gilenya欧盟2011-03-17
  fingolimod
  官方记录
• Fampyra欧盟2011-07-20
  fampridine
  官方记录
• Aubagio欧盟2013-08-26
  teriflunomide
  官方记录
• Lemtrada欧盟2013-09-12
  alemtuzumab
  官方记录
• Tecfidera欧盟2014-01-30
  dimethyl fumarate
  官方记录
• Plegridy欧盟2014-07-18
  peginterferon beta-1a
  官方记录
• Mavenclad欧盟2017-08-22
  cladribine
  官方记录
• Ocrevus欧盟2018-01-08
  ocrelizumab
  官方记录
• Mayzent欧盟2020-01-13
  siponimod
  官方记录
• Zeposia欧盟2020-05-20
  ozanimod
  官方记录
• Kesimpta欧盟2021-03-26
  ofatumumab
  官方记录
• Ponvory欧盟2021-05-19
  ponesimod
  官方记录
• Vumerity欧盟2021-11-15
  diroximel fumarate
  官方记录
• Briumvi欧盟2023-05-31
  ublituximab
  官方记录
• Riulvy欧盟2025-07-28
  tegomil fumarate
  官方记录
• Cenrifki欧盟2026-06-19
  tolebrutinib
  官方记录
• Lioresal Intrathecal美国1992-06-25
  baclofen
  官方记录
• Betaseron美国1993-07-23
  Interferon beta-1b
  官方记录
• Avonex美国1996-05-17
  Interferon beta-1a
  官方记录
• Copaxone美国1996-12-20
  glatiramer acetate
  官方记录
• Novantrone美国2000-10-13
  Mitoxantrone
  官方记录
• Ampyra美国2010-01-22
  dalfampridine
  官方记录

数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。

在中国开展的临床试验 89L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。

登记为可入组 37

• 招募中NCT04106830
  Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
  观察性 · 2019/01/01Beijing Tiantan Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT04561557
  Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
  早期 I 期 · 干预性 · 2020/09/22Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT05154370
  China National Registry of Neuro-Inflammatory Diseases
  观察性 · 2021/12/15Beijing Tiantan Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT07353216
  Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
  观察性 · 2023/12/01Third Affiliated Hospital, Sun Yat-Sen University
  中国研究中心 1 个：Guangzhou
• 仅邀请入组NCT06643858
  Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
  观察性 · 2023/12/01Beijing Tiantan Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06541626
  Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
  观察性 · 2024/01/01Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  中国研究中心 1 个：Guangzhou
• 招募中NCT06249438
  A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
  I 期 · 干预性 · 2024/03/20RenJi Hospital
  中国研究中心 1 个：Shanghai
• 招募中NCT07653984
  Cohort Study on Neuroimmune Diseases in the Reproductive Age
  观察性 · 2024/04/21Third Affiliated Hospital, Sun Yat-Sen University
  中国研究中心 1 个：Guangzhou
• 仅邀请入组NCT06782958
  Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
  I 期 · 干预性 · 2024/07/05Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
  中国研究中心 1 个：Lanzhou
• 招募中NCT06502015
  Biomarkers in Autoimmune Disease of Nervous System
  观察性 · 2024/07/31Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT06474520
  Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
  不适用 · 干预性 · 2024/08/08Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT06671236
  Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
  I 期 · 干预性 · 2024/11/21Novabio Therapeutics
  中国研究中心 1 个：Zhengzhou
• 招募中NCT06794008
  BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  II 期 · 干预性 · 2024/12/26Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06968039
  Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
  不适用 · 干预性 · 2024/12/31Xuanwu Hospital, Beijing
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT06485232
  Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
  早期 I 期 · 干预性 · 2025/02/28Xuanwu Hospital, Beijing
  中国研究中心 1 个：Beijing
• 招募中NCT07087873
  Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
  不适用 · 干预性 · 2025/05/30Xuanwu Hospital, Beijing
  中国研究中心 1 个：Beijing
• 招募中NCT06939166
  Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
  早期 I 期 · 干预性 · 2025/06/17Tianjin Huanhu Hospital
  中国研究中心 1 个：Tianjin
• 尚未开始招募NCT06607900
  hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
  I 期 · 干预性 · 2025/07/01Xuanwu Hospital, Beijing
  中国研究中心 1 个：Beijing
• 招募中NCT07361094
  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/11/06Beijing Boren Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT07225504
  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  III 期 · 干预性 · 2025/11/11Novartis Pharmaceuticals
  中国研究中心 16 个：Beijing、Changchun、Chongqing、Guangzhou、Hangzhou、Hohhot 等 16 地
• 招募中NCT07305116
  CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
  I 期 · 干预性 · 2025/12/01The Children's Hospital of Zhejiang University School of Medicine
  中国研究中心 1 个：Hangzhou
• 招募中NCT07337785
  CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
  早期 I 期 · 干预性 · 2025/12/12Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT07325292
  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  III 期 · 干预性 · 2026/01/14Sanofi
  中国研究中心 4 个：Beijing、Chengdu、Jiazhuang
• 尚未开始招募NCT07392528
  Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
  早期 I 期 · 干预性 · 2026/03Tianjin Huanhu Hospital
  中国研究中心 1 个：Tianjin
• 尚未开始招募NCT07333196
  Tongji NADs Cohort
  观察性 · 2026/03/01Tongji Hospital
  中国研究中心 1 个：Wuhan

另有 12 项未列出。

中国境外的在招试验 603L2

CT.gov 报告命中 603 项，此处取回并展示最近的 15 项。

• 尚未开始招募NCT06228781
  Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis
  不适用 · 干预性 · 2026/12/01Tianjin Medical University General Hospital
• 尚未开始招募NCT06065670
  Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
  I 期、II 期 · 干预性 · 2026/09/15University of California, San Francisco
  美国
• 尚未开始招募NCT07766213
  Pain Phenotypes in Individuals With Multiple Sclerosis
  观察性 · 2026/08/15Kutahya Health Sciences University
  土耳其
• 招募中NCT07758270
  Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
  观察性 · 2026/08/15Washington University School of Medicine
  美国
• 招募中NCT07759115
  Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
  不适用 · 干预性 · 2026/08/10University of Texas at Austin
  美国
• 尚未开始招募NCT07475377
  Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis
  不适用 · 干预性 · 2026/08/01University of Alabama at Birmingham
  美国
• 尚未开始招募NCT07742579
  Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression
  III 期 · 干预性 · 2026/08Robert Simpson
• 尚未开始招募NCT07723599
  Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study
  观察性 · 2026/08University of Washington
  美国
• 招募中NCT07573241
  Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice
  不适用 · 干预性 · 2026/07/17University of Washington
  美国
• 尚未开始招募NCT07724093
  Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis
  不适用 · 干预性 · 2026/07/15University of Dayton
  美国
• 招募中NCT07287202
  Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
  I 期、II 期 · 干预性 · 2026/07/14Sovargen
  澳大利亚
• 尚未开始招募NCT07710742
  Effects Of Motor Imagery and Sensorimotor Training
  不适用 · 干预性 · 2026/07/09Uludag University
  土耳其
• 尚未开始招募NCT07645937
  Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis
  不适用 · 干预性 · 2026/07/01Hanifi Bal
• 招募中NCT07220252
  Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
  II 期、III 期 · 干预性 · 2026/07/01TG Therapeutics, Inc.
  波兰
• 尚未开始招募NCT07020715
  A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
  II 期 · 干预性 · 2026/07/01University Hospital, Antwerp
  比利时、西班牙

外部标识与链接